Penumbra, Inc. (PEN) Earnings Call Transcript & Summary
April 23, 2025
Earnings Call Speaker Segments
Cecilia Furlong
executiveThanks, Operator, and I appreciate everyone being here today as we go over Penumbra's results for Q1 2025. You can find the press release along with the financial tables — including a reconciliation from GAAP to non-GAAP — under the Investors section of our site, www.penumbrainc.com. On this call, we'll be making forward-looking statements under the safe harbor protections of the Private Securities Litigation Reform Act of 1995, covering things like our financial performance, commercialization efforts, clinical trials, regulatory status, quality, compliance, and business trends. There are certain risks and uncertainties that could cause actual results to differ materially from what's stated or implied in those forward-looking statements, and some of them are described in our 10-K for the year ended December 31, 2024, filed with the SEC. So we'd caution you not to put undue reliance on these forward-looking statements, and we'd encourage you to look at our periodic SEC filings, including that 10-K, for a fuller discussion of these factors and other risks that could impact our future results or the market price of our stock. Penumbra undertakes no duty to update or revise these forward-looking statements because of new information, future events, developments, or anything else. On this call, revenue and gross margin are given on a GAAP basis, whereas operating expenses, operating income, and adjusted EBITDA are given on a non-GAAP basis. The matching GAAP measures and a reconciliation between GAAP and non-GAAP financial measures appear in the press release we posted. Non-GAAP operating expenses and operating income leave out amortization of acquired intangible assets of $2.4 million and non-recurring litigation-related expenses of $4.8 million in Q1 2024, and adjusted EBITDA leaves out those non-recurring litigation-related expenses, stock compensation expense, depreciation and amortization, provision for income taxes, and interest income expenses. Adam Elsesser, Penumbra's Chairman and CEO, will give a business update. Maggie Yuen, our Chief Financial Officer, will follow with a discussion of our financial results for the first quarter of 2025, and Jason Mills, our Executive Vice President of Strategy, will cover our 2025 guidance. With that, I'll hand the call over to Adam Elsesser.
Adam Elsesser
executiveThanks, Cecilia. Good afternoon, everyone, and thanks for being with us on Penumbra's call for the first quarter of 2025. During Q1, our total revenue came in at $324.1 million, which works out to underlying growth of 16.3% versus a year earlier as reported, and 16.9% in constant currency terms. Results for the quarter showed ongoing momentum throughout our core U.S. thrombectomy operation, since the clinical advantages of our proprietary, differentiated CAVT technology are helping us strengthen even further the solid standing we hold in the market. U.S. thrombectomy revenue for the quarter rose 25% compared with a year earlier, reaching $187.9 million, and our U.S. VTE franchise led the business once more, posting total growth of 42% year over year. Strong growth also came from our arterial and stroke businesses, as those products keep capturing share from open surgery and from competing stroke catheters, respectively. These robust top-line results, together with our emphasis on profitable growth and a profitability profile that keeps expanding, produced yet another solid quarter of operating cash flow. Gross margin during the quarter was 66.6%, up 160 basis points from the same period a year earlier, and operating income reached $40.4 million, or 12.4% of revenue, which is 550 basis points higher than the year-ago period; we're still on track and well positioned to reach a gross margin profile above 70% by the close of 2026. I want to speak to the matter of proposed or enacted tariffs along with the current macro backdrop; at present, 100% of our products are manufactured inside the United States at our facilities in Alameda and Roseville, California; on top of that, roughly three-quarters of our raw materials and components are presently sourced within the United States; we're additionally involved in a routine, ongoing effort to optimize our supply chain, which covers, among other things, strategically onshoring certain materials that aren't currently sourced in the U.S. Sales from the U.S. made up 79.2% of total revenue during the quarter. As for China in particular, our original forecast for the rest of the year included just $5 million, which we are now removing because of the current macro environment. Now to our U.S. peripheral business: during the quarter, we achieved strong sequential expansion over the fourth quarter in the overall count of VTE patients treated using our technology. These strong Q1 results highlight the durable growth and momentum of Flash 2.0 in VTE, as 2.0's proven value proposition keeps driving conversions to CAVT for both PE and DVT from anticoagulation, lytics, and other mechanical thrombectomy platforms. Adding Lightning Bolt 12 to the portfolio recently further strengthens our competitive positioning, and Bolt 12's contributions beat expectations during its first full quarter on the market. Our U.S. arterial business likewise posted a solid first quarter, driven by a mix of continued strong growth in Bolt 7 and contributions from Bolt 6X that ramped ahead of expectations, together fueling physician conversion to CAVT from open surgery or the use of lytics. Rapid, continuous innovation is a core tenet of our strategy and a powerful competitive differentiator. Our top goal remains broadening the reach and strengthening our proprietary CAVT portfolio. We see the products we're about to launch as important, and we expect they'll keep fueling a fundamental change in the way clot gets tackled and managed; beyond that, we'll put money into more innovation throughout our embolization and access offerings; halfway through March, the FDA granted clearance for Ruby XL, a newly introduced, bigger diagnostic catheter-compatible peripheral coil. Ruby XL will build on what our peripheral embolization portfolio already does, carrying our market leadership into larger vessel anatomies. Ruby XL is going to be used for conditions including pelvic congestion, endoleaks, and TIPS varices, among others. The FDA's clearance for Ruby XL arrived sooner than anticipated, which is why we've started an accelerated inventory build to back a market launch either late in Q2 or early in Q3, so we can rapidly satisfy the strong physician interest in the product we've witnessed so far. As our product portfolio keeps growing, we'll make strategic, measured investments in our commercial team to bolster and sharpen attention on the big market opportunities before us, setting that team up to succeed. We keep growing and drawing on our market access initiatives to raise awareness of CAVT's clinical and health economic advantages. At the SIR Annual Scientific Meeting in Nashville at the close of March, two more retrospective analyses centered on DVT and ALI management with CAVT were delivered. Compared with anticoagulation for treating DVT and open surgery for treating ALI, respectively, those analyses showed CAVT's capacity to shorten hospital length of stay and boost the rate of patient discharge to the home setting, a plus for patients treated with CAVT and for healthcare systems alike. The health economic data included in these studies is being presented to hospital executives. We're at an early point in using our market access initiatives to spotlight CAVT's many benefits relative to alternative interventional options and anticoagulation; we'll keep investing in and expanding our clinical evidence base and keep building on our work to drive greater adoption of our CAVT technology and reach the substantial number of patients globally who suffer from clot burden anywhere in the body. Turning to our neurovascular business, our U.S. stroke thrombectomy franchise posted another solid quarterly performance, with the clinical and procedural advantages of our market-leading aspiration portfolio fueling volume growth beyond our expectations and beyond the market. The commercial introduction late in the first quarter of our next-generation RED 72 catheter, nicknamed Silver Label, drew significant physician enthusiasm. Silver Label has generated strong interest, adoption, and utilization so far, with our R&D teams' ongoing focus on technology innovation delivering a meaningful gain in trackability. With Silver Label, we keep pushing the mechanical aspiration space ahead and set a higher standard for how well catheters track, while Thunderbolt gives us another substantial chance to tackle and enhance how quickly clot can be removed through a procedure that is both safe and straightforward, which extends even further the dominant leadership spot we already hold in the market. As for our Thunder trial, during the first quarter of 2025, we handed the clinical data over to the FDA so it could be reviewed. We'll share further updates down the road when it makes sense and stay thrilled about bringing CAVT into the neurovascular arena. We came into 2025 carrying considerable momentum throughout our business, and that carried through into Q1 of the year, driven by our CAVT portfolio and the compelling value it offers. Staying dedicated to ongoing innovation, producing top-tier clinical and health economic evidence, and making strategic bets on our commercial organization puts us in position to achieve lasting growth together with rising profitability and to build on our standing as the top thrombectomy company worldwide. At this point I'll hand things over to Maggie, who will walk through our financial results for the first quarter of 2025.
Maggie Yuen
executiveThanks, Adam. Good afternoon, everybody. During today's call, I'll go over our financial performance for Q1 of 2025. Revenue and gross margin figures are presented on a GAAP basis, whereas operating expenses and operating income are non-GAAP. You can find the comparable GAAP figures along with our GAAP-to-non-GAAP reconciliation in the press release we posted. For Q1, which closed on March 31, 2025, total revenues came in at $324.1 million, up 16.3% as reported and up 16.9% on a constant currency basis versus Q1 of 2024. Sales by geography during Q1 of 2025 split 79.2% U.S. and 20.8% international. Growth in our U.S. region reached 22.5%, fueled by a 25% rise in our thrombectomy franchise versus the prior-year period. Our international regions fell 2.5% as reported and 0.1% in constant currency, largely because China revenue dropped by $6.7 million versus the prior-year period, partly offset by a $5 million gain across all other international regions. Total revenue rose 2.7% sequentially, mainly on higher U.S. thrombectomy revenue and higher EMEA revenue, partly offset by a $5.4 million decline in China revenue versus Q4 of 2024. Turning to revenue by product, our global thrombectomy business generated $226.5 million in Q1 of 2025, up 20.7% as reported and up 21.2% in constant currency versus the prior-year period, primarily fueled by 25% growth in our U.S. thrombectomy business. Our international thrombectomy business rose 3.3%, which includes a $4.7 million decline in China revenue. If you set aside the China region's impact, our international thrombectomy revenue climbed 18.2% versus the prior-year period. Given macroeconomic conditions in China, we anticipate continued year-over-year headwinds from our China business during Q2 of 2025. Revenue from our embolization and access business reached $97.6 million in Q1 of 2025, up 7.3% as reported and up 8.1% in constant currency, mainly fueled by growth in the U.S. Gross margin for Q1 of 2025 came in at 66.6%, versus 65% for Q1 of 2024, a 160 basis point gain driven by favorable thrombectomy product mix across our regions and strong productivity improvements. As we look ahead to Q2 2025, we continue to anticipate a higher thrombectomy product mix, offset by greater manufacturing investment to support new product launches, including, as Adam noted earlier, a one-quarter expediting cost for Ruby XL, which will leave our gross margin in Q2 2025 similar to or slightly below Q1 2025. As we progress into the second half of 2025, we anticipate sequential gross margin expansion. Now let's turn to our non-GAAP operating expenses, non-GAAP operating income and margin, and adjusted EBITDA. Operating costs across the quarter came to $175.5 million, which equals 54.2% of revenue, versus $161.8 million, or 58.1% of revenue, in the comparable quarter a year ago. R&D spending in Q1 2025 totaled $22.1 million, or 6.8% of revenue, against $24.6 million, or 8.8% of revenue, in Q1 2024 — a figure that shows $4.5 million in savings from winding down our immersive business, partially offset by ongoing product development investment. SG&A for Q1 2025 reached $153.5 million, or 47.3% of our Q1 2025 revenue, versus $137.2 million, or 49.2% of revenue, in Q1 2024, mainly from continuing investment in the commercial and market access team, partly offset by savings from the immersive business wind down. As anticipated, SG&A in Q1 2025 carries heavier seasonal expenditures for payroll taxes and our annual sales meeting. With continued investment in the right sales levers, we're glad to see leverage on our G&A expenditures this quarter; operating income came in at $40.4 million, or 12.4% of revenue, against operating income of $19.3 million, or 6.9% of revenue, in the same period a year earlier. Adjusted EBITDA was $59.6 million, or 18.4% of total revenue, versus $36.3 million, or 13.5%, in last year's first quarter. Moving to cash flow and balance sheet, we closed the first quarter of 2025 with cash, cash equivalents, and marketable securities of $378.8 million and no debt — up $38.7 million sequentially on strong operating profitability, and that includes our initial capital expenditure investment in Costa Rica of $10.7 million, which isn't currently scheduled to come online until 2027. We anticipate positive operating cash flow trends continuing in 2025 and beyond. Now I'd like to hand the call to Jason to discuss our 2025 guidance.
Jason Mills
executiveThanks, Maggie, and good afternoon to all of you. In line with the guidance approach we described during our previous call, and even though we have taken China revenue out of our forecast, we are reaffirming our full-year total revenue guidance range of 12%-14% growth year-over-year; for our U.S. thrombectomy business, we are lifting our guidance to growth between 20% and 21% year-over-year. In addition, we reaffirm our expectations for expansion of gross margin and operating margin for 2025; that brings our prepared remarks to a close. Operator, we are ready to take questions now.
Bob Marcus
analystOh, that's wonderful. Congratulations on a solid quarter. I appreciate your taking my question.
Adam Elsesser
executiveCertainly.
Bob Marcus
analystPerhaps as a starting point, the U.S. thrombectomy growth was really impressive. You highlighted that 42% VTE figure. I was hoping you might provide a bit more detail on stroke compared with peripheral, plus the market trends you're observing across those two different markets.
Adam Elsesser
executiveYeah. To begin with, I appreciate the remark about the VTE business. That's now the second quarter in a row, as you're aware, in which we've recorded that kind of growth. That wave, so to speak, is progressing through. When it comes to the other businesses, we do tend to emphasize certain ones. Breaking out each segment isn't something we'll do. Clearly, it becomes complex from quarter to quarter. Our view is that, measured by volume, our stroke business this quarter expanded well above the market. As you're aware, near the close of the quarter we launched the new RED 72, and it generated considerable interest along with an early uptick as the quarter ended. Being ready for Thunderbolt has truly put us in a strong position. There's an enormous amount of chatter out there and enthusiasm surrounding it. Clearly, when it comes to those stroke procedures, the two most critical elements are, first, you must be able to deliver the catheter there both safely and rapidly; with this new catheter, in that size category, I believe we are, unquestionably, essentially the market leader on that front. Being able to extract it very fast is, I think, a benefit Thunderbolt will demonstrate. I'd say our stroke business is in fairly excellent shape; regarding the arterial side, as I mentioned during the prepared remarks, we were essentially exactly where we'd hoped to be, perhaps even slightly ahead with certain newer products in terms of how swiftly physicians have adopted them.
Bob Marcus
analystGreat. Perhaps just one brief follow-up. Once more, looking down the P&L, EPS results were quite good this quarter. When I examine it, it isn't only, I mean, you enjoyed gross margin upside, you enjoyed SG&A improvement. I'd say the largest variance compared to the street and how we were contemplating it was in R&D. Perhaps I'll combine them here. What's your thinking? Do you think you're perhaps nearer the upper end of the operating margin guidance given the first quarter result? I realize it's hard to lift after only one quarter. What's your thinking regarding R&D moving forward? Thanks very much.
Adam Elsesser
executiveYeah. Allow me to take the R&D question, and after that Maggie can sort of speak to where we land in the yearly sort of cadence, so to speak. R&D, the particular spend on R&D, as you're aware, is never sort of a linear spend. Certain things occur at certain moments in the process, and so it hasn't been a linear spend. A portion of that also reflects sort of the anniversary of immersive healthcare. That's why I believe partly you see it lower since we're now sort of into the comparisons without having immersive healthcare in there. Maggie can speak to sort of the cadence across the remainder of the year.
Maggie Yuen
executiveAbsolutely, Adam. I believe you're right about that, and you also highlighted in the prepared remarks the estimated savings of roughly $10 million per quarter from winding down the immersive business — around half of that showed up in the R&D line. So on a year-over-year basis, particularly as a percentage of revenue, that's where the improvement becomes visible. You can view it as fairly baseline moving forward, with ongoing investment. And if you look at last quarter for comparison, you'll see this is the direction we're heading.
Adam Elsesser
executiveSure. I’ll state what should be clear here. We highlighted R&D and the remarkable innovation we’ve delivered across all the years this company has existed. We aren’t backing off from putting money into R&D. I believe we took some time during the prepared remarks to discuss that; we will keep investing, where it makes sense, in products that must be created so that clot removal keeps improving and improving, and on the embolization access side. The pipeline is strong; it just turned out that this quarter was affected because a couple of those items came in somewhat lower.
Bob Marcus
analystGreat. Good quarter. Thanks.
Adam Elsesser
executiveThank you.
Larry Biegelsen
analystHello. This is Lay, and I'm on the line on behalf of Larry. Thanks for fielding our questions, and congratulations on a strong beginning to the year. My first question is about Thunderbolt. Should we anticipate a standard FDA review for this product? Could you describe the main metrics you think physicians will consider when comparing it with other catheters — first pass effect, procedure time, and so on? I have a follow-up.
Adam Elsesser
executiveYes. Regarding the first portion of your question, it was submitted as a 510(k). What they are really examining is the clinical data. Naturally, they had already reviewed many of the other elements earlier. You can never be certain. I don't want to have made predictions specifically about that product in the past. I think I'll remain disciplined and refrain from forecasting its timing once more. Up to now, nothing unexpected has emerged. The metrics that were roughly assessed in the submission are, clearly, the primary and secondary endpoints — essentially, how we perform on the standard measures. The additional items you brought up, such as first pass effect, are all clearly recorded and will certainly be a pertinent component of the conversation. Clearly, we think we ought to perform well relative to those expectations; that hardly needs saying. What I believe is distinctive beyond those — so it's in addition to, not in place of — is something that genuinely hasn't been talked about previously, which is not merely procedure time, but the measure of how long the device, once engaged in any manner, requires to extract the clot. That's where the distinction lies. Versions of these catheters have already been available on the market, clearly, for a great many years. So what we're actually examining now is how the CAV technology works. And once more, that will be more of an intuitive check for physicians as they begin to grasp it and observe it. But I think, clearly, the initial stage will simply be the conventional metrics you already listed.
Larry Biegelsen
analystThat's useful, thank you. Turning to my follow-up question: since the Stryker and Inari deal, there have been reports of disruption among sales forces. I just wanted to get a sense of what you're observing on the ground, and how that might be shaping the market's dynamics. Thanks.
Adam Elsesser
executiveIn organizations, personnel come and go. When a merger occurs, things have certainly played out that way. That can happen sometimes. Other times it doesn't. What I can say is that we feel quite sure we're capturing a meaningful share — not owing to the merger, but instead because, frankly, and without trying to sound arrogant, our product is simply superior. As an increasing number of individuals discuss it, that word-of-mouth circulates from one physician to another; we're watching more people join in. My belief is that the merger isn't the reason. The reason, in my view, is that our product is the better one.
Pito Chickering
analystHi there, good afternoon, everyone. I appreciate you taking my questions. I just want to return to the guidance for a moment. The sole adjustment you made was pulling $5 million of China revenue that had previously been included. At this point, you're not presuming that gets compensated for by extra growth from U.S. thrombectomy. Should that be our takeaway?
Adam Elsesser
executiveYes. We are certainly removing that from what we expect, since — and once more, it's a fairly modest figure relative to prior years — that had been roughly the topic we'd discussed over the last few quarters concerning China. Jason, would you like to add something?
Jason Mills
executiveSure. Here's how I'd put it, Pete, and thanks for asking. I'd say the gap between how Q1 actually came in and what consensus had been expecting for Q1 was roughly $8 million to $9 million. What we're referring to in China — and the bulk of it sits in the second quarter — comes to about $5 million. If you simply take the first quarter performance together with what we've now said regarding China, the net increase works out to $4 million. Clearly that's taking place, with that better-than-expected showing coming largely from the United States and U.S. thrombectomy.
Pito Chickering
analystAll right, that's helpful. Could you describe the trends you're observing in thrombectomy across international markets, excluding China? This quarter appeared fairly robust. What's driving that momentum? Have reimbursements for your offerings shifted in any newly entered regions? And once those China-related pressures ease, ought we to expect that expansion to persist? Thanks.
Jason Mills
executiveYes, thanks for picking up on that and recognizing it. In every place where CAVT is available, we're certainly experiencing growth for the very same reasons it's happening in the U.S. Naturally, since it represents a smaller share of overall revenue, the proportion is lower. At this point, the U.S. accounts for almost 80% of what we bring in, so it's going to deliver a disproportionate share of expansion. Given that our products are manufactured domestically and also sold domestically, the timing is arguably quite favorable. CAVT is gaining ground in nations worldwide that possess the means and willingness to cover its cost. We're achieving genuine momentum in those places. My expectation is that this will persist. Over time, I believe we'll bring more countries on board. That prospect has us quite enthusiastic. Having said all that, and I realize I've covered a lot of ground, the U.S. should still outpace those markets simply owing to the scale of the opportunity here, the reimbursement environment, the evidence we're now discussing through our market access efforts—all of these factors, I believe, mean the U.S. will fuel much of this growth across the coming couple of years. Other regions of the globe will present excellent opportunities as they emerge, yet they'll likely take on a more significant part in later years.
Bill Plovanic
analystYep. Thanks so much.
Jason Mills
executiveThank you.
Mark McKinley
analystHi, everybody. McKinley here, filling in for Margaret this evening. Appreciate you letting us ask a few things. From what I gather, the focus right now is securing Thunderbolt's approval before any conversation about when that launch would happen. Thinking back to the time Flash and Bolt each got the green light and likewise had to go through the VAX for 6X and 12, I'm curious whether the market access efforts have cut down how long that takes. And if the answer is no, have those efforts at least eased the burden on your commercial group, freeing them to concentrate on physicians you're trying to convert instead of dealing with those heavier administrative chores?
Adam Elsesser
executiveYes. Excellent question. When it comes to the vascular business, clearly, I'd say we've got a solid grip on that. Part of it involved bringing on the right quantity of reps, and since we've done so, we've had the staffing and bandwidth to handle it. This year's influx of new accounts left us somewhat unprepared; regarding neuro, with respect to Thunderbolt, that problem doesn't really apply to us. We've been handling every neuro account with relative ease. We're able to reach them. For many years now, we've rolled out products again and again. Never have we really brought up the VAX question. In a hospital setting, I believe the case we make for Thunderbolt will be quite persuasive. My feeling is VAX won't be the sticking point. Of course, we still have to clear it; that's a gate we always face, but in my view it isn't something that hasn't already been accounted for in our projections. I'd say we simply manage it better now, given how much more experience we have across that entire broad set of accounts.
Mark McKinley
analystAll right, that's clear. As a quick follow-up, I'd like to ask about how Arterial performed. You brought up demand and the growing contribution, clearly from both 7 and 6X. For Jason, I'm curious whether you could give us at least a directional sense of where growth landed this quarter relative to either U.S. throm or that VT growth, and beyond that, what ought we to anticipate for the rest of the year?
Jason Mills
executiveSure. I'll take that first, and Adam can chime in after. Arterial has been a bright spot for our U.S. business; it stayed a bright spot for our U.S. business during the first quarter. Adam, in his prepared remarks, explained the reasons to you.
Adam Elsesser
executiveHonestly, it comes down to the products themselves and CAVT, Bolt 7 along with Bolt 6X — that's the initial complete quarter where they've been available, and both are performing extremely, extremely strongly among a patient population that remains underpenetrated. Within our U.S. thrombectomy franchise, we anticipate continued robust arterial growth.
Mark McKinley
analystThat's fantastic. Appreciate it once more.
Bill Plovanic
analystWonderful. Thank you. Good evening, and thanks for fielding my questions. If I may, since we're discussing Lightning Bolt 6X and 7 as they're being introduced, I'm just wondering — when you consider how those products will grow, and you weigh units against ASPs — my understanding is that once you move to 6X, you're also combining it with SendIt as we head into BTK. So I'm just asking, what sort of balance between pricing and volume are you observing? We're still at the beginning of this. Is this a situation where 6X paired with SendIt will deliver something like two or three times the magnitude of what you currently get per case compared with the standard catheter? I have a follow-up.
Adam Elsesser
executiveYeah. To start with, nearly all of our expansion during the last quarter came from volume — price played no role whatsoever. If you focus mainly on 6X, those represent cases we hadn't been handling previously. They were cases performed through open surgery owing to the artery's size. Clearly, price simply reflects volume; these are new cases. There's hardly any distinction between 6X and 7. You aren't transitioning from, "Oh, I previously used 7. Now I'm using 6X. It costs somewhat more." The overwhelming majority of this is clearly volume. We pointed that out in the prepared script.
Bill Plovanic
analystAll right. Is there anything new regarding coronary? How about bringing the CAVT technology into that area?
Adam Elsesser
executiveYes. That's a fair question. The coronary segment keeps performing well for us. People who utilize it on a consistent basis clearly believe it has transformed how they work in a major way. What we really need to determine is whether it's needed inside the coronary arteries. Usually, clots there behave quite differently. Exceptions always exist. Should you recall the CHEETA study from quite a few years back, the amount of time needed for that device to clear the clot was extremely brief — roughly a couple of minutes, slightly more than 1 minute, 1.5 minutes, if I recall the precise figure. What could we possibly bring to that scenario today? Even a prep period adding 1 or 2 minutes to it may not be ideal. We'll keep investigating that. Certain exceptions exist where, in the coronary, we can offer something that works well for extracting more chronic or tougher clot. Broadly speaking, though, our current product performs extremely well in the coronary. Clearly, that remains a strong business for us. All these years later, it simply isn't expanding at the pace those other ones are.
Bill Plovanic
analystYeah. If I may, regarding tariffs, ultimately it sounds like there's not much of an effect on you, considering where you produce and where you get your materials. Still, it seems — and this is somewhat repetitive — but with the strong beat in the first quarter, the guidance, particularly when it comes to operating margin or operating profitability, looks very cautious. I'm just curious about what's behind that?
Adam Elsesser
executiveYeah. I believe you already captured it. We've recently had the experience of leaning too far forward. It's only the first quarter, early in the year, and we're going to maintain our cautious stance. I think you've got it.
Bill Plovanic
analystThank you.
Adam Elsesser
executiveThank you.
Travis Steed
analystHey, appreciate you taking the question. I'd like to dig a bit deeper into Ruby XL, this new offering, and perhaps into markets where we don't have as much familiarity. Could you walk us through what this product is and what the market potential looks like? Are we talking about something in the tens of millions, or is this a hundred million-plus kind of opportunity?
Adam Elsesser
executiveSure. I'll start by explaining what it is. It's based on the very same underlying platform as all of our peripheral coils, which tend to be bigger in diameter, softer, and longer, so you get greater control and can fill the space you're working in far more quickly and far more fully. That softness translates into improved packing density. We're now making that coil bigger in terms of diameter, length, and so forth, so we can use it in places where coils aren't normally deployed, or where they are, you're dealing with coils lacking those same qualities of being extremely soft and extra long. It's somewhat early for us. Let's get our first cases completed once we have product in hand, and after that we'll begin to offer you a clearer picture of how far this can reach. If you could give us a bit of time to finish those initial cases, I'd be glad to try to size that market more thoroughly for you on upcoming calls.
Travis Steed
analystExcellent; that answers everything I needed. I have no further questions.
Adam Elsesser
executiveOf course. Thanks so much.
Ryan Zimmerman
analystHey, appreciate you fielding our questions. I suppose I have two. You're putting in that work over in Costa Rica. You could argue that's the ideal location. Tariff-related shifts aren't hitting you. Some money's already been invested, correct? Does your strategy shift in any way regarding growing down there, leveraging that as a launchpad toward a wider global push? I realize nothing's settled at the moment, but I'm simply wondering whether the way the market's behaving has led you to hold off and reconsider that somewhat differently.
Adam Elsesser
executiveYeah. No, that's a terrific question. I'm happy you brought it up. What I'd say is that initiative is moving forward; we put pen to paper on a deal for the property, and the plant will get constructed and everything along those lines. This takes multiple years to complete. Prior to it being operational, it should go live at some point during 2027. Can't say yet which direction things will go. Should circumstances return to where tariffs are typical and this is no longer the hot subject it currently is, then clearly that becomes the next logical spot for us to grow. We'll move certain goods down there that could carry somewhat better margins when produced in the U.S., and we'll capture a meaningful margin upside from that too. How fast we can grow down there is fairly swift, roughly 2 years until we're operational, so to speak. Should things not shift and we remain in a climate where tariffs drive much of what we choose, then we've got a site beyond the U.S. capable of essentially serving the remaining global market minus any tariff exposure on goods we ship out of here; that setup gives us considerable room to maneuver. Honestly, having production spread across more than a single broad region, even though our 2 facilities sit just a few hours apart and remain within the same state, strikes me as clearly the smart move for us. Regardless, we're able to adapt, and it simply affords us substantial optionality in a few years when we make that call.
Ryan Zimmerman
analystAll right. As a follow-up, a novel medication got cleared, a fresh clot-busting treatment, back in March, I think, and it provides roughly one five-second intravenous push instead of, say, some of those agents that act more slowly, such as Activase. Right now I'm referring specifically to neurovascular, Adam, since you likely know. I'm simply curious if you expect this to affect thrombectomy demand soon, as it gets introduced and doctors perhaps feel somewhat more inclined to give it a shot when faced with what might be some of your technology.
Adam Elsesser
executiveYeah. My sense is these are truly distinct patient groups. Some patients lack a clot and instead have lacunar strokes much further down in the brain, places where catheters cannot reach, not even the tinier distal ones, and there a medication of that kind would deliver enormous value. I have not heard anyone, including non-interventional neurologists, discuss reverting to an earlier-stage drug to test whether it outperforms thrombectomy at this point. That simply hasn't reached my ears; it makes far more sense and seems far more probable that it serves extremely distal strokes of the sort where catheters do not fit whatsoever.
Ryan Zimmerman
analystOkay. Thank you, Adam.
Adam Elsesser
executiveYeah. Thank you.
Clayton Marsh
executiveAlright, thank you for fielding the question, everyone. I’ve got two quick items, and I’ll put both out there right away. First, regarding arterial — I’m really just after some additional clinical detail about the initial 6X launch, the main pieces of feedback you got on those BTK cases, and how ready physicians have been to alter their treatment approaches. Second, on Thunderbolt — clearly, your existing data for distal clot thrombectomy isn’t strong, even if there’s more sensed skew. Is there some sort of technological element that could allow modulated aspiration to hit distal clots more effectively than the tech available now? Many thanks.
Adam Elsesser
executiveSure, those are two solid questions. Let's begin with the arterial side and how things are progressing there. Here's the thing — with arterial work, our competition is open surgery. When you're able to remove the clot in roughly 1 or 2 minutes of device time, or 3 minutes, versus going the open surgery route, those physicians are going to choose you. It comes down to how predictable the procedure is. With modulated aspiration 6X, predictability goes up another notch. It gets the job done. It's quick. That word of mouth starts building; we witnessed that firsthand. People talk about it a lot, there's a great deal of enthusiasm surrounding it. Again, I believe these things arrive in waves. It's not as though everyone comes on board simultaneously; that's not how it works when you've got a massive landmark clinical trial, or a reimbursement decision, or a guideline update. This is word of mouth. What should I be doing right now? What's my colleague doing? Is it worth trying? I gave it a shot. Oh, wow, that's impressive. Word of mouth grows. It arrives in waves. We've clearly witnessed that on the VTE side, where we've had 2 quarters of this kind of wave, and we're bringing people on board for the upcoming round of conversions. That's a thrilling moment. The identical pattern is occurring on the arterial side since the product simply performs. It performs in smaller vessels. It performs in the larger ones with seven. I believe we're going to witness that. Regarding Thunderbolt moving further distal, at present Thunderbolt is paired in a trial alongside our 72, our 68, and our 62. Sixty-two definitely has the ability to reach a bit further distal. Once you truly venture into the areas where you're not on label, meaning the M3, you are on label in M2 where our existing technology can be used. When you head into areas where you're not on label, which some of those distal trials that you'd stint treatment demonstrated, the situation changes; and the 43 has performed extremely well. As vessels get smaller and smaller, clot has a tendency — often — to be somewhat less difficult to extract, provided you can simply get the catheter in there; so we'll wait and see. No final decisions have been reached regarding how small a catheter you can pair Thunderbolt with, or whether there's an advantage as you go smaller and smaller. But we'll keep you posted.
Clayton Marsh
executiveGreat. Thanks, Adam.
Adam Elsesser
executiveThank you.
Richard Newitter
analystThank you for fielding our questions, and congratulations on the quarter. Perhaps I'll start with U.S. stroke. I'm aware that for U.S. neuro-thrombectomy, you've been growing at or near 20% across the past several quarters. I realize the year-over-year comparison is tougher this quarter, but is it reasonable to think you landed in that vicinity? Or could you give us a sense of how you compare against the market's rate?
Adam Elsesser
executiveYes. Richard, a few times over, everybody asks for the exact figures. Naturally, we're going to head down this quite difficult road of going number by number, quarter by quarter, and that won't do any good. We plainly highlighted VTE given how notable that expansion was, the impact it delivered, and how large that market is. On stroke, like I've mentioned, our performance was strong. We definitely outpaced the market. The market, as you're aware, has been expanding at a modest pace, yet it hasn't shown the type of growth we've witnessed on the arterial or venous side. It was evident from our own data, examining locations performing cases that previously weren't doing them. We truly didn't lose anyone, and we observed a sizable set of new physicians more or less switch over. I believe we're faring quite well when it comes to stroke.
Richard Newitter
analystAll right. I suppose if you could give some sense of roughly how large the U.S. market is, and then I'll just ask my follow-up right now. I'm not asking whether it's included in guidance. My guess is that it isn't, but you have several new launches on the way. Q1 was entirely volume growth. Might there be a chance for pricing to act as a tailwind or an additional driver in the back half thanks to these new products? If you're willing to say whether any of that is being baked into guidance, thanks.
Adam Elsesser
executiveYeah. The major item we've discussed, clearly, is that Thunderbolt remains outside guidance until approval happens. Obviously, we'll add it in. We've stated that previously. Thunderbolt is the product that likely carries the clearest price for us. Ironically, actually, if you consider the overwhelming majority of what people do, whether that involves a stent retriever plus costly guide catheters and everything along those lines, on a per-case basis we actually won't cost more, yet for us, using Thunderbolt will deliver a pricing advantage. That's correct. The broader matter of lifting price — perhaps that wasn't your question, but just in case it was — given this particular moment, many companies we compete against are pushing their prices up. That's where their growth comes from; they simply declare, "My product now costs X." That's their growth. It isn't volume growth. It isn't market growth. In fact, for some of them, it's a decline, just masked by higher prices. Hospitals are all discussing that right now. I've been pulled into a few of those conversations, and everybody's hearing about it. We haven't done that, and it benefits us since we have plenty of growth arriving through volume, through new cases; when times get difficult, refraining from that really matters a great deal. People recall it favorably for a long while. I just wanted to ensure that was clear — we are not raising our price.
Matthew O'Brien
analystHello?
Adam Elsesser
executiveHello. We got you now.
Matthew O'Brien
analystAm I audible to you at this point? All right. That's strange. My mic wasn't switched off, so let's go back to that peripheral figure, Adam — it was extremely impressive. Could you spend a moment describing what the market looks like right now regarding how that product is expanding on the PE side? Apologies — I mean Flash 2.0 in particular, but on the PE side, the DVT side. Is there any particular area where you're noticing a turning point? I'm not sure whether it's one area or the other. Are you beginning to observe that penetration and switching away from lytics might be speeding up? I've got one more question after this.
Adam Elsesser
executiveYes. To provide a bit of background, clearly when we did a couple two quarters ago, we held a bigger share of the DVT and PE markets. Naturally, a greater share of this expansion is now arriving in PE, though DVT is still showing it too. Once more, it genuinely isn't arriving from lytics to the same degree, even though there will always be the occasional case, but the overwhelming bulk is actually arriving from other companies, other mechanical offerings. Again, not to sound dismissive or clever, but CAVT is simply superior. A computer is what you use to actuate the valve. It operates considerably more quickly. We've already described what that looks like. As an increasing number of people grasp that, they hear about it, they hear it from their friends, they attend meetings, they discuss it, and it draws people in. At SIR, dozens and dozens of individuals who had never once used our product approached us and wanted to have a conversation, whereas previously that wasn't something they were willing to do; we're witnessing that everywhere. Once more, it's a superior product. We won't sit back and coast. I mentioned this during the prepared remarks. Innovation will keep going, with a priority focus on these CAVT products, so that we remain ahead and keep making the removal of clot more and more routine for these patients. That's how it goes. These things arrive in waves. They aren't linear. I have to say that again and again; that isn't a hidden message about anything — it's simply how the process works. A process unfolds when people speak with one another and then convert. It's a wonderful moment. It's very enjoyable to have people who spent many, many years being skeptical now come to us and be the ones mainly calling us rather than us calling them; it speaks to the remarkable R&D work and, honestly, the patience and, honestly, the commitment our commercial team shows toward their customers.
Matthew O'Brien
analystUnderstood. All right, thanks for that. Next, a question for Maggie — and I'm certain Jason will cut this off — but that gross margin gain during the quarter was, once again, pretty astonishing. Peripheral is performing very strongly. My guess is those carry some quite attractive gross margins. Is there any chance we could reach 70% gross margins somewhat sooner than roughly the close of next year? I realize there's still quite a distance to travel, but could we begin approaching a figure like that even late in this year, or perhaps Q2 of next year? Thank you.
Maggie Yuen
executiveYes. I appreciate the question. Discussing that is a bit early, though I'd say all things are moving in the proper direction. You can, after all, examine our forecast for this year's sequential improvement, which resembles last year's. The way our product mix gains affect gross margin follows a comparable pattern. Likewise, I noted as well that during the second quarter, because of some stepped-up investment in Ruby XL aimed at refining our manufacturing process, our margin might come in slightly level in the second quarter relative to the first quarter — yet that's merely investment timing, and we remain on the proper path. Thank you.
David Rescott
analystIs this coming through? Hi there.
David Rescott
analystAm I audible to you?
Adam Elsesser
executiveYes, we hear you. Hey, David.
David Rescott
analystOh, hi there. Wonderful. I appreciate you fielding the questions, and congratulations on this quarter. Adam, my recollection is that during the prior quarter, you discussed a greater emphasis on investing in certain U.S. embolization businesses. Could you perhaps elaborate on what you're thinking regarding that, where you believe the payoff might lie, and whether that could assist in returning to steadier growth in embolization? If that's the case, at what level would you estimate normalized growth for the market?
Adam Elsesser
executiveYes. Thank you, David. That's an excellent question. We've discussed this on a few occasions. Our investment spans 2 areas. First, clearly, regarding innovation, we've been developing new technologies for embolization. Ruby XL is among them, designed to address a distinctive and quite meaningful problem. Assuming the product performs as we enter the clinic with it, in the manner we foresee and anticipate, I believe it will be a quite beneficial and meaningful product and definitely contribute to growth. The second area where we're putting money is something I've mentioned before: ensuring the commercial team possesses the bandwidth to stay focused. We have many products. A vascular rep who now sells a suite of embolization tools, with one more still to launch, plus a suite of CAVT tools. At times the customer bases differ. That's a great deal to handle, and those teams need to concentrate. We'll share additional details on that, likely during the coming quarters, about what that entails at a granular level. Those are the 2 areas, so that both the embo team, the embo group, can concentrate, so to speak, and thrombectomy can remain focused. To me, that's essential, because otherwise you're simply rushing about and incapable of accomplishing everything.
David Rescott
analystAll right, great. So regarding the medium-sized vessel category and the stroke segment, I believe roughly 3 or 4 months have passed since that data came out. I'm curious whether your thinking has evolved about what that market might look like, or what it could become following the data we observed. What I mean is, a number of the checks we've conducted, though they aren't a positive for the overall thrombectomy market, appear to indicate that the aspiration market might gain something from how those trials read out. I'd like to hear any fresh perspective on this, and also whether Thunderbolt might have some part to play in that space. Thanks.
Adam Elsesser
executiveYeah. That's an excellent question. It's quite evident that when you go fairly distal into the M3 and beyond using a stent retriever, that's not something you should be doing. Honestly, for those of us who have concentrated on aspiration as a company from the start, that was rather apparent. There's recently published data involving our RED 43 demonstrating a markedly different outcome in vessels that are more distal. I believe you're correct. If that's the approach you're taking, an appropriately sized aspiration catheter is what you ought to be using. In my view, aspiration does offer an advantage in that region. When it comes to Thunderbolt, it remains an open question just how small a catheter can deliver a benefit through the concept of modulated aspiration. At present, Thunderbolt is available on RED 62. That formed part of our trial; clearly it isn't as small as 43, yet it can certainly reach what you might call mid-sized vessels. Those aren't standardized terms. Definitions vary somewhat from person to person. Where a 62 will fit, it has demonstrated itself to be a highly effective instrument in the trial alongside Thunderbolt. I believe our position is very strong when it comes to ultimately helping all those patients in cases where the catheter is able to fit. That's something we've consistently done, and we intend to keep doing it.
Cecilia Furlong
executiveThanks, Operator. Our management team and I want to express our appreciation once more for everyone being here with us today, and for the attention you've shown toward Penumbra. We're eager to bring you up to speed during this call covering our second quarter.
Operator
operatorThis concludes today's conference call. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.